Cyclooxygenase-2 (COX2) inhibitors have also been described to reduce MDSC numbers and to have immunosuppressive function in solid tumors, but they have not been tested in hematological malignancies [82, 83]. The gene discussed is PTGS2; the disease is hematologic disorder.